The 12-month results from the ECLIPSE AF trial, conducted by CardioFocus, Inc., have been published in Circulation: Arrhythmia & Electrophysiology. The study demonstrated a 90.2% freedom from clinically significant atrial arrhythmia among paroxysmal atrial fibrillation (AF) patients undergoing pulmonary vein isolation (PVI) using the Centauri™ System’s optimized WAVE1™ pulsed field ablation (PFA) waveform. This system, now CE marked and available in the EU and UK, has successfully treated over 6000 patients. The trial included both paroxysmal and persistent AF patients, showing an overall 80.2% 12-month freedom from clinically significant atrial arrhythmia. The optimized PFA waveform achieved an 89% chronic PVI durability rate per pulmonary vein.
Dr. Ante Anić, Head of Electrophysiology at University Hospital Split, emphasized the importance of waveform science in delivering safe and effective PFA therapy. The study's peer-reviewed results confirm that using a traditional point-by-point workflow with focal catheters and an optimized waveform yields excellent clinical outcomes. Dr. Johan Vijgen, Division Chief of Electrophysiology at Jessa Hospital, highlighted the critical role of remapping in optimizing the PFA waveform and procedural workflow, leading to durable PVI and exceptional long-term arrhythmia survival rates.
